Breast cancer other imaging studies: Difference between revisions

Jump to navigation Jump to search
Line 58: Line 58:
==Positron emission mammography==
==Positron emission mammography==
*'''PEM is still under investigation.'''
*'''PEM is still under investigation.'''
*High-resolution [[fluorodeoxyglucose]] PEM with compression with 2 mm in-plane resolution has been studied for detection of small malignancies
*High-resolution [[fluorodeoxyglucose]] PEM with compression with 2 mm in-plane resolution has been studied for detection of small malignancies <ref name="pmid20871992">Schilling K, Narayanan D, Kalinyak JE, The J, Velasquez MV, Kahn S et al. (2011) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=20871992 Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging.] ''Eur J Nucl Med Mol Imaging'' 38 (1):23-36. [http://dx.doi.org/10.1007/s00259-010-1588-9 DOI:10.1007/s00259-010-1588-9] PMID: [https://pubmed.gov/20871992 20871992]</ref> <ref name="pmid23239242">Kalles V, Zografos GC, Provatopoulou X, Koulocheri D, Gounaris A (2013) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=23239242 The current status of positron emission mammography in breast cancer diagnosis.] ''Breast Cancer'' 20 (2):123-30. [http://dx.doi.org/10.1007/s12282-012-0433-3 DOI:10.1007/s12282-012-0433-3] PMID: [https://pubmed.gov/23239242 23239242]</ref>
*'''The procedure'''
*'''The procedure'''
:*This is a modified PET scan method and hence patients are prepared as for PET scan.
:*This is a modified PET scan method and hence patients are prepared as for PET scan.
Line 70: Line 70:
:*Hence, '''PEM is not recommended for screening or as a tool to exclude the likelihood of [[Cancer|malignancy]] in suspicious breast masses or abnormal [[mammography]].'''
:*Hence, '''PEM is not recommended for screening or as a tool to exclude the likelihood of [[Cancer|malignancy]] in suspicious breast masses or abnormal [[mammography]].'''
:*Nevertheless PEM is promising for the preoperative assessment of disease extension
:*Nevertheless PEM is promising for the preoperative assessment of disease extension
[[Image:Positron Emission Mammography.jpg|center|600px|thumb|'''Positron emission mammography.''' By Yamamoto, Yayoi; Tasaki, Youichiro; Kuwada, Yukiko; Ozawa, Yukihiko; Katayama, Atsushi; Kanemaki, Yoshihide; Enokido, Katsutoshi; Nakamura, Seigo; Kubouchi, Kouichi; Morita, Satoshi; Noritake, Mutsumi; Nakajima, Yasuo; Inoue, Tomio - (2 July 2013). "Positron emission mammography (PEM): reviewing standardized semiquantitative method". Annals of Nuclear Medicine 27 (9): 795–801. DOI:10.1007/s12149-013-0748-y. PMC: 3830195., CC BY 4.0, <nowiki>https://commons.wikimedia.org/w/index.php?curid=65304896</nowiki>]]
[[Image:Positron Emission Mammography.jpg|center|600px|thumb|'''Positron emission mammography.''' By Yamamoto, Yayoi; Tasaki, Youichiro; Kuwada, Yukiko; Ozawa, Yukihiko; Katayama, Atsushi; Kanemaki, Yoshihide; Enokido, Katsutoshi; Nakamura, Seigo; Kubouchi, Kouichi; Morita, Satoshi; Noritake, Mutsumi; Nakajima, Yasuo; Inoue, Tomio - (2 July 2013). "Positron emission mammography (PEM): reviewing standardized semiquantitative method". Annals of Nuclear Medicine 27 (9): 795–801. DOI:10.1007/s12149-013-0748-y. PMC: 3830195., CC BY 4.0, <nowiki>https://commons.wikimedia.org/w/index.php?curid=65304896</nowiki>]]<ref name="pmid23814402">Glass SB, Shah ZA (2013) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=23814402 Clinical utility of positron emission mammography.] ''Proc (Bayl Univ Med Cent)'' 26 (3):314-9. PMID: [https://pubmed.gov/23814402 23814402]</ref>
 
*


==Reference==
==Reference==

Revision as of 22:18, 29 April 2019

Breast Cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Breast cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT scan

MRI

Echocardiography or Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Breast cancer other imaging studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Breast cancer other imaging studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Breast cancer other imaging studies

CDC on Breast cancer other imaging studies

Breast cancer other imaging studies in the news

Blogs on Breast cancer other imaging studies

Directions to Hospitals Treating Breast cancer

Risk calculators and risk factors for Breast cancer other imaging studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2], Ammu Susheela

Overview

Other diagnostic studies for breast cancer include modified MRI utilities (high-field strength MRI, magnetic resonance spectroscopy, and diffusion weighted imaging, breast-specific gamma imaging, positron emission mammography, scintimammography, thermography and bone scan.

Scintimammography or breast-specific gamma imaging (BSGI)

  • Gamma cameras with 2 to 3 mm in-plane resolution in a mammographic configuration are used
  • Concept of BSGI is based on the accumulation of technetium-99m sestamibi in intracellular mitochondria of breast cancers cells.[1]
  • Compared to normal cells there is an increased number if intracellular mitochondria in breast cancer cells.[2]
  • Procedure
  • First 25 mCi of technetium-99m sestamibi is being injected intravenously
  • Following the injection of the radioisotope, The patient is scanned for 5 to 10 minutes.
  • Mild breast compression is applied as of conventional mammography.
  • Craniocaudal and mediolateral oblique views for each breast
  • This is an adjuvant imaging method and hence images will be interpreted with respect to the patient's mammograms, ultrasounds, and clinical findings.[3]
  • If indicated, BSGI compatible biopsy system is available to direct tissue sampling for the patients with small lesions not seen on other imaging modalities.
  • Compared to MRI, BSGI showed an equal sensitivity and higher specificity for the detection of breast cancer.
  • BSGI is recommended for use in the preoperative assessment of disease extension in breast cancer patients. or:
  • To check breast lumps that do not show up clearly on a mammogram because of:
  • Scar tissue from previous surgery or radiation therapy
  • Dense breast tissue
  • Breast implants
  • When multiple tumors are seen in the breast
  • To scan the lymph nodes in the armpit (axilla) to see if they contain cancer
  • Because of a very limited available DATA at the moment, BSGI is not recommended for screening or as a tool to exclude the likelihood of malignancy in suspicious breast masses or abnormal mammography.
Mammography and scintimammography of breast carcinoma. Images courtesy of Vassilios Papantoniou, Spyridon Tsiouris, Ekaterini Mainta, Varvara Valotassiou, Michael Souvatzoglou, Maria Sotiropoulou, Lydia Nakopoulou, Dimitrios Lazaris, Androniki Louvrou, Maria Melissinou, Artemis Tzannetaki, Ioannis Pirmettis, John Koutsikos and Cherry Zerva - "Imaging in situ breast carcinoma (with or without an invasive component) with technetium-99m pentavalent dimercaptosuccinic acid and technetium-99m 2-methoxy isobutyl isonitrile scintimammography". Breast Cancer Research 7 (1). DOI:10.1186/bcr948. PMC: 1064097., CC BY 2.0, https://commons.wikimedia.org/w/index.php?curid=58579597

Bone Scan

  • A bone scan uses bone-seeking radioactive materials (radiopharmaceuticals) and a computer to create a picture of the bones. It is used to see if breast cancer has spread (metastasized) to the bones.[4]
  • A bone scan may be done if:[5]
  • Alkaline phosphatase in the blood is increased
  • There are lymph nodes in the armpit (axillary lymph nodes) that can be felt
  • The primary breast tumor is larger than 5 cm
  • The woman has aches and pains that may be caused by bone metastases
  • A bone scan is not done in women who have stage I breast cancer.

Thermography

  • Digital infrared thermal imaging (DITI) is a type of thermography which is used in the screening of breast cancer
  • An infrared thermal camera takes pictures of the areas of different temperature in the breasts.[6]
  • The camera displays these patterns as a sort of heat map.
  • Since the presence of cancerous growth is associated with the excessive formation of blood vessels and inflammation in the breast tissue.
  • On the infrared images, these higher temperatures could be detected.[7]

Benefits

  • Non-invasive procedure
  • Non-contact procedure (does not compress the breast)
  • No exposure to radiation, (safe)
  • It can detect vascular changes in breast tissue associated with breast cancer many years in advance of other methods of screening.
  • It can be used for all women, including those with dense breast tissue and breast implants.
  • Hormonal changes do not affect results.

Drawbacks[8][9]

Breast thermography. This is a high-resolution mid-range infrared image depicting cancer in the right breast by the high-energy blood vessels. Image courtesy of Philip P. Hoekstra, III, Ph.D.

Positron emission mammography

  • PEM is still under investigation.
  • High-resolution fluorodeoxyglucose PEM with compression with 2 mm in-plane resolution has been studied for detection of small malignancies [10] [11]
  • The procedure
  • This is a modified PET scan method and hence patients are prepared as for PET scan.
  • Mild compression as of conventional mammography
  • Craniocaudal and mediolateral oblique views for each breast
  • This is an adjuvant imaging method and hence images will be interpreted with respect to the patient's mammograms, ultrasounds, and clinical findings.
  • if indicated, PEM-compatible biopsy system is available to direct tissue sampling for the patients with small lesions not seen on other imaging modalities.
  • Sensitivity 86 to 91 percent
  • Specificity91 to 93 percent
  • Major drawback is that PEM cannot reliably detect low-grade malignancies.
  • Hence, PEM is not recommended for screening or as a tool to exclude the likelihood of malignancy in suspicious breast masses or abnormal mammography.
  • Nevertheless PEM is promising for the preoperative assessment of disease extension
Positron emission mammography. By Yamamoto, Yayoi; Tasaki, Youichiro; Kuwada, Yukiko; Ozawa, Yukihiko; Katayama, Atsushi; Kanemaki, Yoshihide; Enokido, Katsutoshi; Nakamura, Seigo; Kubouchi, Kouichi; Morita, Satoshi; Noritake, Mutsumi; Nakajima, Yasuo; Inoue, Tomio - (2 July 2013). "Positron emission mammography (PEM): reviewing standardized semiquantitative method". Annals of Nuclear Medicine 27 (9): 795–801. DOI:10.1007/s12149-013-0748-y. PMC: 3830195., CC BY 4.0, https://commons.wikimedia.org/w/index.php?curid=65304896

[12]

Reference

  1. Jones EA, Phan TD, Blanchard DA, Miley A (2009) Breast-specific gamma-imaging: molecular imaging of the breast using 99mTc-sestamibi and a small-field-of-view gamma-camera. J Nucl Med Technol 37 (4):201-5. DOI:10.2967/jnmt.109.063537 PMID: 19914975
  2. Rechtman LR, Lenihan MJ, Lieberman JH, Teal CB, Torrente J, Rapelyea JA et al. (2014) Breast-specific gamma imaging for the detection of breast cancer in dense versus nondense breasts. AJR Am J Roentgenol 202 (2):293-8. DOI:10.2214/AJR.13.11585 PMID: 24450668
  3. Brem RF, Floerke AC, Rapelyea JA, Teal C, Kelly T, Mathur V (2008) Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. Radiology 247 (3):651-7. DOI:10.1148/radiol.2473061678 PMID: 18487533
  4. Sugihara T, Koizumi M, Koyama M, Terauchi T, Gomi N, Ito Y et al. (2017) Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors. Ann Nucl Med 31 (10):719-725. DOI:10.1007/s12149-017-1202-3 PMID: 28864931
  5. Cook GJ, Azad GK, Goh V (2016) Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment. J Nucl Med 57 Suppl 1 ():27S-33S. DOI:10.2967/jnumed.115.157867 PMID: 26834098
  6. Omranipour R, Kazemian A, Alipour S, Najafi M, Alidoosti M, Navid M et al. (2016) Comparison of the Accuracy of Thermography and Mammography in the Detection of Breast Cancer. Breast Care (Basel) 11 (4):260-264. DOI:10.1159/000448347 PMID: 27721713
  7. Mambou SJ, Maresova P, Krejcar O, Selamat A, Kuca K (2018) Breast Cancer Detection Using Infrared Thermal Imaging and a Deep Learning Model. Sensors (Basel) 18 (9):. DOI:10.3390/s18092799 PMID: 30149621
  8. Brkljacić B, Miletić D, Sardanelli F (2013) Thermography is not a feasible method for breast cancer screening. Coll Antropol 37 (2):589-93. PMID: 23941008
  9. Kolarić D, Herceg Z, Nola IA, Ramljak V, Kulis T, Holjevac JK et al. (2013) Thermography--a feasible method for screening breast cancer? Coll Antropol 37 (2):583-8. PMID: 23941007
  10. Schilling K, Narayanan D, Kalinyak JE, The J, Velasquez MV, Kahn S et al. (2011) Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging. Eur J Nucl Med Mol Imaging 38 (1):23-36. DOI:10.1007/s00259-010-1588-9 PMID: 20871992
  11. Kalles V, Zografos GC, Provatopoulou X, Koulocheri D, Gounaris A (2013) The current status of positron emission mammography in breast cancer diagnosis. Breast Cancer 20 (2):123-30. DOI:10.1007/s12282-012-0433-3 PMID: 23239242
  12. Glass SB, Shah ZA (2013) Clinical utility of positron emission mammography. Proc (Bayl Univ Med Cent) 26 (3):314-9. PMID: 23814402